Contraception in cancer survivors – an expert review Part I. Breast and gynaecological cancers

References

• Plu-Bureau G, Maitrot-Mantelet L, Hugon-Rodin J, et al. Hormonal contraceptives and venous thromboembolism: an epidemiological update. Best Pract Res Clin Endocrinol Metab. 2013;27:25–34.
   PubMed Web of Science ®Google Scholar
• Toivonen J, Luukkainen T, Allonen H. Protective effect of intrauterine release of levonorgestrel on pelvic infection: three years' comparative experience of levonorgestrel- and copper-releasing intrauterine devices . Obstet Gynecol. 1991;77:261–264.
   PubMed Web of Science ®Google Scholar
• Demeestere I, Brice P, Peccatori FA, et al. No evidence for the benefit of gonadotropin-releasing hormone agonist in preserving ovarian function and fertility in lymphoma survivors treated with chemotherapy: final long-term report of a prospective randomized trial. JCO. 2016;34:2568–2574.
   PubMed Web of Science ®Google Scholar
• Lambertini M, Boni L, Michelotti A, et al. Ovarian suppression with triptorelin during adjuvant breast cancer chemotherapy and long-term ovarian function, pregnancies, and disease-free survival: a randomized clinical trial. JAMA. 2015;314:2632–2640.
   PubMed Web of Science ®Google Scholar
• Moore HCF, Unger JM, Phillips K-A, et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med. 2015;372:923–932.
   PubMed Web of Science ®Google Scholar
• Taylor CW, Kirby AM. Cardiac side-effects from breast cancer radiotherapy. Clin Oncol (R Coll Radiol). 2015;27:621–629.
   PubMed Web of Science ®Google Scholar
• Yeboa DN, Evans SB. Contemporary breast radiotherapy and cardiac toxicity. Semin Radiat Oncol. 2016;26:71–78.
   PubMed Web of Science ®Google Scholar
• Nolan MT, Russell DJ, Negishi K, et al. Meta-analysis of association between mediastinal radiotherapy and long-term heart failure. Am J Cardiol. 2016;118:1685–1691.
   PubMed Web of Science ®Google Scholar
• Koo E, Henderson MA, Dwyer M, et al. Management and prevention of breast cancer after radiation to the chest for childhood, adolescent, and young adulthood malignancy. Ann Surg Oncol. 2015;22:S545–S551.
   PubMed Web of Science ®Google Scholar
• Thavendiranathan P, Nolan MT. An emerging epidemic: cancer and heart failure. Clin Sci. 2017;131:113–121.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Medical eligibility criteria for contraceptive use; 2015 [cited 2019 Mar 15]. Available from: www.who.int/reproductivehealth/publications/family_planning/MEC-5/en
   Google Scholar
• Faculty of Sexual and Reproductive Healthcare of the Royal College of Obstetricians and Gynaecologists. UK medical eligibility criteria for contraceptive use; 2016 [cited 2017 Jan 15]. Available from: https://www.fsrh.org/standards-and-guidance/documents/ukmec-2016/.
   Google Scholar
• Global Cancer Observatory. Breast; 2018 [cited 2019 Mar 19]. Available from: http://gco.iarc.fr/today/data/factsheets/cancers/20-Breast-fact-sheet.pdf
   Google Scholar
• Zavos A, Valachis A. Risk of chemotherapy-induced amenorrhea in patients with breast cancer: a systematic review and meta-analysis. Acta Oncol. 2016;55:664–670.
   PubMed Web of Science ®Google Scholar
• Pérez-Fidalgo JA, Roselló S, García-Garré E, et al. Incidence of chemotherapy-induced amenorrhea in hormone-sensitive breast cancer patients: the impact of addition of taxanes to anthracycline-based regimens. Breast Cancer Res Treat. 2010;120:245–251.
   PubMed Web of Science ®Google Scholar
• Chien AJ, Duralde E, Hwang R, et al. Association of tamoxifen use and ovarian function in patients with invasive or pre-invasive breast cancer. Breast Cancer Res Treat. 2015;153:173–181.
   PubMed Web of Science ®Google Scholar
• Valachis A, Tsali L, Pesce LL, et al. Safety of pregnancy after primary breast carcinoma in young women: a meta-analysis to overcome bias of healthy mother effect studies. Obstet Gynecol Surv. 2010;65:786–793.
   PubMed Web of Science ®Google Scholar
• Partridge AH, Gelber S, Peppercorn J, et al. Fertility and menopausal outcomes in young breast cancer survivors. Clin Breast Cancer. 2008;8:65–69.
   PubMed Web of Science ®Google Scholar
• Partridge A, Gelber S, Gelber RD, et al. Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from International Breast Cancer Study Group Trials V and VI. Eur J Cancer. 2007;43:1646–1653.
   PubMed Web of Science ®Google Scholar
• Tham Y-L, Sexton K, Weiss H, et al. The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane. Am J Clin Oncol. 2007;30:126–132.
   PubMed Web of Science ®Google Scholar
• Francis PA, Regan MM, Fleming GF, et al. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015;372:436–446.
   PubMed Web of Science ®Google Scholar
• Silva C, Caramelo O, Almeida-Santos T, et al. Factors associated with ovarian function recovery after chemotherapy for breast cancer: a systematic review and meta-analysis. Hum Reprod. 2016;31:2737–2749.
   PubMed Web of Science ®Google Scholar
• Pagani O, Regan MM, Walley BA, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014;371:107–118.
   PubMed Web of Science ®Google Scholar
• Yoo C, Yun MR, Ahn J-H, et al. Chemotherapy-induced amenorrhea, menopause-specific quality of life, and endocrine profiles in premenopausal women with breast cancer who received adjuvant anthracycline-based chemotherapy: a prospective cohort study. Cancer Chemother Pharmacol. 2013;72:565–575.
   PubMed Web of Science ®Google Scholar
• Sisti JS, Collins LC, Beck AH, et al. Reproductive risk factors in relation to molecular subtypes of breast cancer: results from the nurses' health studies. Int J Cancer. 2016;138:2346–2356.
   PubMed Web of Science ®Google Scholar
• Ellingjord-Dale M, Vos L, Tretli S, et al. Parity, hormones and breast cancer subtypes – results from a large nested case-control study in a national screening program. Breast Cancer Res. 2017;19:10.
   PubMed Web of Science ®Google Scholar
• Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet. 1996;347:1713–1727.
   PubMed Web of Science ®Google Scholar
• Rosenberg L, Boggs DA, Wise LA, et al. Oral contraceptive use and estrogen/progesterone receptor-negative breast cancer among African American women. Cancer Epidemiol Biomarkers Prev. 2010;19:2073–2079.
   PubMed Web of Science ®Google Scholar
• Phipps AI, Chlebowski RT, Prentice R, et al. Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. J Natl Cancer Inst. 2011;103:470–477.
   PubMedGoogle Scholar
• Cibula D, Gompel A, Mueck AO, et al. Hormonal contraception and risk of cancer. Hum Reprod Update. 2010;16:631–650.
   PubMed Web of Science ®Google Scholar
• Lyytinen HK, Dyba T, Ylikorkala O, et al. A case–control study on hormone therapy as a risk factor for breast cancer in Finland: intrauterine system carries a risk as well. Int J Cancer. 2010;126:483–489.
   PubMed Web of Science ®Google Scholar
• Soini T, Hurskainen R, Grénman S, et al. Levonorgestrel-releasing intrauterine system and the risk of breast cancer: a nationwide cohort study. Acta Oncol. 2016;55:188–192.
   PubMed Web of Science ®Google Scholar
• Mørch LS, Hannaford PC, Lidegaard Ø. Ø. Contemporary hormonal contraception and the risk of breast cancer. N Engl J Med. 2018;378:1265–1266.
   PubMedGoogle Scholar
• Jareid M, Thalabard J-C, Aarflot M, et al. Levonorgestrel-releasing intrauterine system use is associated with a decreased risk of ovarian and endometrial cancer, without increased risk of breast cancer. Results from the NOWAC Study. Gynecol Oncol. 2018;149:127–132.
   PubMed Web of Science ®Google Scholar
• Dominick S, Hickey M, Chin J, et al. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen. Cochrane Database Syst Rev. 2015;12:CD007245.
   Google Scholar
• Trinh XB, Tjalma WA, Makar AP, et al. Use of the levonorgestrel-releasing intrauterine system in breast cancer patients. Fertil Steril. 2008;90:17–22.
   PubMed Web of Science ®Google Scholar
• Medica ACO, Stark SS, Hadnott TN, et al. Use of emergency contraception among female young adult cancer survivors. Fertil Steril. 2018;109:1114–1120.e1.
   PubMed Web of Science ®Google Scholar
• Maslow B-S, Morse CB, Schanne A, et al. Contraceptive use and the role of contraceptive counseling in reproductive-aged women with cancer. Contraception. 2014;90:79–85.
   PubMed Web of Science ®Google Scholar
• Güth U, Huang DJ, Bitzer J, et al. Contraception counseling for young breast cancer patients: a practical needs assessment and a survey among medical oncologists. Breast. 2016;30:217–221.
   PubMed Web of Science ®Google Scholar
• Cardoso F, Loibl S, Pagani O, et al. The European Society of Breast Cancer Specialists’ recommendations for the management of young women with breast cancer. Eur J Cancer. 2012;48:3355–3377.
   PubMed Web of Science ®Google Scholar
• Güth U, Huang DJ, Bitzer J, et al. Unintended pregnancy during the first year after breast cancer diagnosis. Eur J Contracept Reprod Health Care. 2016;21:290–294.
   PubMed Web of Science ®Google Scholar
• National Institute of Cancer. Fertility preservation and cancer [in French]; 2013 [cited 2016 Oct 19]. Available from: www.agence-biomedecine.fr/IMG/pdf/cp_rapport_fertilite_cancer-2.pdf
   Google Scholar
• National Cancer Institute. Cancer stat facts: uterine cancer [cited 2016 Oct 19]. 2016. Available from: https://seer.cancer.gov/statfacts/html/corp.html
   Google Scholar
• Blanc B, Lazard A, Estrade JP, et al. Contraceptive methods after gynecological and breast cancer. Bull Acad Natl Med 2010;194:521–527. discussion 529-30.
   PubMed Web of Science ®Google Scholar
• Bruegl AS, Djordjevic B, Batte B, et al. Evaluation of clinical criteria for the identification of Lynch syndrome among unselected endometrial cancer patients. Cancer Prev Res (Phila). 2014;7:686–697.
   PubMed Web of Science ®Google Scholar
• Lee NK, Cheung MK, Shin JY, et al. Prognostic factors for uterine cancer in reproductive-aged women. Obstet Gynecol. 2007;3:655–662.
   Google Scholar
• Rodolakis A, Biliatis I, Morice P, et al. European Society of Gynecological Oncology Task Force for Fertility Preservation: clinical recommendations for fertility-sparing management in young endometrial cancer patients. Int J Gynecol Cancer. 2015;7:1258–1265.
   Google Scholar
• Garg K, Soslow RA. Endometrial carcinoma in women aged 40 years and younger. Arch Pathol Lab Med. 2014;138:335–342.
   PubMed Web of Science ®Google Scholar
• Faubion SS, MacLaughlin KL, Long ME, et al. Surveillance and care of the Gynecologic Cancer Survivor. J Womens Health (Larchmt). 2015;24:899–906.
   PubMed Web of Science ®Google Scholar
• Colombo N, Carinelli S, Colombo A, et al. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23:vii27–vii32.
   PubMed Web of Science ®Google Scholar
• Randall TC, Kurman RJ. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet Gynecol. 1997;90:434–440.
   PubMed Web of Science ®Google Scholar
• Laurelli G, Di Vagno G, Scaffa C, et al. Conservative treatment of early endometrial cancer: preliminary results of a pilot study. Gynecol Oncol. 2011;120:43–46.
   PubMed Web of Science ®Google Scholar
• Pal N, Broaddus RR, Urbauer DL, et al. Treatment of low-risk endometrial cancer and complex atypical hyperplasia with the levonorgestrel-releasing intrauterine device. Obstet Gynecol. 2018;131:109–116.
   PubMed Web of Science ®Google Scholar
• Dashti SG, Chau R, Ouakrim DA, et al. Female hormonal factors and the risk of endometrial cancer in Lynch syndrome. JAMA. 2015;314:61–71.
   PubMed Web of Science ®Google Scholar
• Lin MCH, Burkholder KA, Viswanathan AN, et al. Involution of latent endometrial precancers by hormonal and non-hormonal mechanisms. Cancer. 2009;115:2111–2118.
   PubMed Web of Science ®Google Scholar
• Schwarz EB, Hess R, Trussell J. Contraception for cancer survivors. J Gen Intern Med. 2009;24:S401–S406.
   PubMed Web of Science ®Google Scholar
• Patel A, Schwarz EB., Society of Family Planning. Cancer and contraception. Release date May 2012. SFP guideline #20121. Contraception. 2012;86:191–198.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Cancer of the cervix uteri (invasive). SEER incidence and US death rates, age-adjusted and age-specific rates, by race; 2018 [cited 2018 Oct 19]. Available from http://seer.cancer.gov/csr/1975_2010/browse_csr.php?sectionSEL=5&pageSEL=sect_05_table.07.html
   Google Scholar
• Dominick SA, McLean MR, Whitcomb BW, et al. Contraceptive practices among female cancer survivors of reproductive age. Obstet Gynecol. 2015;126:498–507.
   PubMed Web of Science ®Google Scholar
• Appleby P, Beral V, Berrington de González A, et al. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. International Collaboration of Epidemiological Studies of Cervical Cancer. Lancet. 2007;370:1609–1621.
   PubMed Web of Science ®Google Scholar
• Moodley M, Moodley J, Chetty R, et al. The role of steroid contraceptive hormones in the pathogenesis of invasive cervical cancer: a review. Int J Gynecol Cancer. 2003;13:103–110.
   PubMed Web of Science ®Google Scholar
• Castellsagué X, Díaz M, Vaccarella S, et al. Intrauterine device use, cervical infection with human papillomavirus, and risk of cervical cancer: a pooled analysis of 26 epidemiological studies. Lancet Oncol. 2011;12:1023–1031.
   PubMed Web of Science ®Google Scholar
• Averbach S, Silverberg MJ, Leyden W, et al. Recent intrauterine device use and the risk of precancerous cervical lesions and cervical cancer. Contraception. 2018 [Apr 17]. doi:10.1016/j.contraception.2018.04.008
   Web of Science ®Google Scholar
• Frega A, Scardamaglia P, Piazze J, et al. Oral contraceptives and clinical recurrence of human papillomavirus lesions and cervical intraepithelial neoplasia following treatment. Int J Gynaecol Obstet. 2008;100:175–178.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Cancer stat facts: ovarian cancer; 2018 [cited 2019 Mar 19]. Available from: https://seer.cancer.gov/statfacts/html/ovary.html
   Google Scholar
• Rousset-Jablonski C, Selle F, Adda-Herzog E, et al. Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumors: guidelines from the French national network dedicated to rare gynaecological cancer. Bull Cancer. 2018;105:299–314.
   PubMed Web of Science ®Google Scholar
• Beral V, Doll R, Hermon C, et al. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet. 2008;371:303–314.
   PubMed Web of Science ®Google Scholar
• Iodice S, Barile M, Rotmensz N, et al. Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis. Eur J Cancer. 2010;46:2275–2284.
   PubMed Web of Science ®Google Scholar
• Zapata LB, Whiteman MK, Marchbanks PA, et al. Intrauterine device use among women with ovarian cancer: a systematic review. Contraception. 2010;82:38–40.
   PubMed Web of Science ®Google Scholar
• Curtis KM, Tepper NK, Jatlaoui TC, et al. US medical eligibility criteria for contraceptive use, 2016. MMWR Recomm Rep. 2016;65:1–103.
   Web of Science ®Google Scholar
• Royal College of Obstetricians and Gynaecologists. The management of gestational trophoblastic disease. Green–top guideline no. 38. London: RCOG; 2010.
   Google Scholar
• Stone M, Bagshawe KD. An analysis of the influence of maternal age, gestational age, contraceptive method and primary mode of treatment of patients with hydatidiform mole on the incidence of subsequent chemotherapy. BJOG. 1979;86:782–792.
   Google Scholar
• Costa H, Doyle P. Influence of oral contraceptives in the development of post molar trophoblastic neoplasia: a systematic review. Gynecol Oncol. 2006;100:579–585.
   PubMed Web of Science ®Google Scholar